Published in final edited form as:

Mol Pharm. 2012 March 5; 9(3): 539–545. doi:10.1021/mp200375x.

Different effect of hydrogelation on anti-fouling and circulation properties of dextran–iron oxide nanoparticles

Priya Prakash Karmali¹, Ying Chao², Ji-Ho (Joe) Park³, Michael J. Sailor⁴, Erkki Ruoslahti^{1,5}, Sadik C. Esener⁶, and Dmitri Simberg^{2,7}

¹Cancer Research Center, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Rd., La Jolla, CA 92037, USA

²Moore's Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, USA

³Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, South Korea

⁴Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093 USA

⁵Vascular Mapping Center, Sanford-Burnham Medical Research Institute at UCSB, 1105 Life Sciences Technology Bldg, University of California Santa Barbara, CA, 93106-9610 USA

⁶Department of Nanoengineering, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 USA

Abstract

Premature recognition and clearance of nanoparticulate imaging and therapeutic agents by macrophages in the tissues can dramatically reduce both the nanoparticle half-life and delivery to the diseased tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate recognition by liver and spleen macrophages and greatly prolongs circulation times *in vivo*. Understanding the mechanisms by which hydrogels achieve this “stealth” effect has implications for the design of long-circulating nanoparticles. Thus, the role of plasma protein absorption in the hydrogel effect is not yet understood. Short-circulating dextran-coated iron oxide nanoparticles could be converted into stealth hydrogel nanoparticles by crosslinking with 1-chloro-2,3-epoxypropane. We show that hydrogelation did not affect the size, shape and zeta potential, but completely prevented the recognition and clearance by liver macrophages *in vivo*. Hydrogelation decreased the number of hydroxyl groups on the nanoparticle surface and reduced the binding of the anti-dextran antibody. At the same time, hydrogelation did not reduce the absorption of cationic proteins on the nanoparticle surface. Specifically, there was no effect on the binding of kininogen, histidine-rich glycoprotein, and protamine sulfate to the anionic nanoparticle surface. In addition, hydrogelation did not prevent activation of plasma kallikrein on the metal oxide surface. These data suggest that: (a) a stealth hydrogel coating does not mask charge interactions with iron oxide surface and (b) the total blockade of plasma protein absorption is not required for maintaining iron oxide nanoparticles’ long-circulating stealth properties. These data illustrate a novel, clinically promising property of long-circulating stealth nanoparticles.

Keywords

iron oxide; nanoworms; CLIO; SPIO; kininogen; clearance; plasma; stealth; liver

⁷Corresponding author (dsimberg@ucsd.edu).

Introduction

Sequestration of nanoscale drug/gene delivery systems by macrophages is one of the most serious limitations of *in vivo* nanomedicine¹. Multiple defense mechanisms with overlapping specificities efficiently recognize and sequester the injected foreign materials². The ability to control and reduce immune recognition of nanoparticles can have an enormous impact on the provision of nanomedicines by enabling more efficient imaging and therapy. The most common strategy for preventing immune recognition of nanoparticles and prolonging their half-life in circulation is to decorate the surface of the nanoparticles with repelling hydrophilic polymers such as polyethylene or polypropylene oxides. The mechanism of the prolonged-circulation effect is not clear, but it is thought to be caused by a non-specific impermeable barrier that sterically prevents the access of plasma proteins and cell receptors³.

Dextran-coated superparamagnetic iron oxide nanoparticles (SPIO) are widely used in the clinic as magnetic resonance imaging (MRI) contrast agents. Following intravenous injection, 50–150 nm SPIO become extensively coated by plasma proteins and are cleared from systemic circulation by resident macrophages in the liver, spleen, and lymph nodes, with a half-life of 1–3 hours in humans^{4–6}. The structural, physical, and surface properties of iron oxides are well-studied^{7,8}. Typical SPIO consist of Fe₃O₄ crystals of ~5nm size embedded in a meshwork of branched dextran (10–40 kDa). Fe₃O₄ crystals are slightly anionic due to the partial dissociation of Fe(OH)₃^{9,10}. Using a high-resolution differential proteomic approach, we previously identified plasma proteins that bind to SPIO⁵. Cationic plasma proteins including high molecular weight kininogen (HMWK) and histidine-proline rich glycoprotein (HPRG) bind to the particles due to the anionic component of the nanoparticles, while immunoglobulins and lectins likely bind to dextran's resultant sugar residues^{11–13}.

Recently, crosslinked dextran iron oxide nanoparticles (CLIO) have been described¹⁴. These nanoparticles are prepared by reacting SPIO with 1-chloro-2, 3-epoxypropane (epichlorohydrin). The alkylating-crosslinking properties of epichlorohydrin result in the formation of a hydrated hydrogel coat^{15,16}. Recently, we described the synthesis and targeting properties of elongated CLIO nanoparticles, dubbed magnetic nanoworms (MNW)^{17,18}. Magnetic nanoworms exhibit long-circulating properties *in vivo* (up to a 12-hour half-life in mice)¹⁸. The crosslinked dextran forms highly hydrated hydrogel^{16,19}. By analogy with PEGylated coatings, one could assume that the dextran hydrogel forms a steric barrier that prevents protein absorption of plasma proteins³. Here, we studied the effect of dextran crosslinking and hydrogelation on MNW recognition by plasma proteins. Our study reveals unexpected mechanisms related to non-fouling and bioinert properties of long-circulating nanoparticles, and provides important pointers for the future design and fabrication of stealth nanomedicines.

Results

First, we studied the effects of crosslinking on the physicochemical properties of nanoparticles. Hereafter we abbreviate crosslinked magnetic nanoworms as CL-MNW and non-crosslinked ones as NCL-MNW. We prepared NCL-MNW by precipitating 20kDa dextran with iron salts as described^{20,21}. From these nanoparticles, we prepared crosslinked CL-MNW by treatment with 1-chloro-2, 3-epoxypropane (epichlorohydrin)¹⁷ (Fig. 1A). Transmission electron microscopy (Fig. 1B, Supplemental Fig. S1 for low magnification) showed that both NCL-MNW and CL-MNW appeared as worm-like clusters of electron-dense iron oxide crystals, consistent with what has been described previously¹⁷.

In order to exclude artifacts, we subsequently performed cryo-TEM, which confirmed the worm-like shape (Supplemental Fig. S2). Both TEM and cryo-TEM confirmed that the worm-like shape of nanoparticles is not affected by crosslinking (Fig. 1C). Dynamic light scattering measurements (Fig. 1D, upper panel) showed that nanoparticle size did not change with the hydrogelation, with initial 96 nm NCL-MNW resulting in 105 nm CL-MNW. The zeta potential values of both types of nanoparticles in water were neutral, with -1.65mV for SPIO and -2.1mV for CLIO (Fig. 1D, lower panel).

In order to determine the effect of crosslinking on nanoparticle circulation *in vivo*, both CL-MNW and NCL-MNWs were injected into mice. CL-MNW demonstrated around 10-fold prolongation of half-life *in vivo* compared to NCL-MNW (Fig. 2A–B). The prolonged clearance of CL-MNW correlated well with these particles' reduced uptake by Kupffer macrophages in the liver (Fig. 2B). The methylating and crosslinking effect of epichlorohydrin was required in order to attain these long-circulating properties. When NCL-MNW were treated with 1-chloropropane 2,3-diol (resulting in CPD-MNW), which has only alkylating but no crosslinking properties, there was no improvement in MNW circulation properties (Fig. 2C).

To investigate the effects of dextran crosslinking on nanoparticle surface, particles were probed with fluorescein-labeled anti-dextran IgG prior to and following crosslinking. The presence of dextran-binding antibodies has been previously shown in human plasma¹². Recognition of CL-MNW by anti-dextran IgG was reduced by 60% compared to NCL-MNW (Fig. 3A–B, *p*-value 0.008), suggesting that some sugar epitopes were destroyed by epichlorohydrin. Epichlorohydrin can crosslink between two adjacent hydroxyl groups, generating one hydroxyl, or it can form epoxy adducts that subsequently hydrolyze to form two hydroxyls (Fig. 1B); therefore, a net decrease in surface hydroxyls is expected. We conjugated methyl red dye through a carboxyl group to the hydroxyls of the nanoparticle coating and measured the absorbance of the resulting conjugates. Methyl red conjugation was about 60% lower in CL-MNW than in NCL-MNW (Fig. 3C–D), suggesting that crosslinking partially destroyed dextran chemical structure and consumed some of its hydroxyls.

We tested whether the stealth effect of epichlorohydrin is caused by an alteration of the sugar structure and/or by a decrease of surface hydroxyls. Branched 500kDa dextran was conjugated to the surface of CL-MNW and NCL-MNW. The conjugation of dextran 500kDa resulted in an increase in the diameter of CL-MNW by $\sim 55\text{nm}$ (Supplemental Fig. S3A). The circulation half-life of Dex500-conjugated NCL-MNW was prolonged by 100%, and Dex500-conjugated CL-MNW was prolonged by 25% (Supplemental Fig. S3B–C), suggesting that intact dextran prevents—rather than promotes—nanoparticle recognition.

In order to test whether MNW crosslinking affects nanoparticulate interaction with total plasma protein, CL-MNW and NCL-MNW were incubated with fresh citrated mouse or human plasma (see Materials and Methods). Since the half-life of NCL-MNW is less than 30 minutes, the proteins that adhere to nanoparticles within 10–30 minutes are likely the most relevant for clearance. Following 10 minutes of incubation with plasma, unbound proteins were completely removed by washing (Supplemental Fig. S4). SDS-PAGE and silver staining of the adhered proteins showed that in these experimental conditions plasma proteins stick to both types of nanoparticles to almost the same extent (Fig. 4A). Previously we demonstrated that high molecular weight kininogen (HMWK) and histidine-proline rich glycoprotein (HPRG) adsorb on SPIO^{5, 22} via the histidine-rich sequences. These sequences are known to bind to the anionic surface and to divalent metals^{23, 24}. Immunoblotting (Fig. 4A for mouse plasma and Supplemental Fig. S4 for human plasma) shows that CL-MNW and NCL-MNW absorb HPRG and HMWK at similar rates. Kallikrein, which in plasma

exists in a complex with HMWK, bound to both types of particles to the same extent (Fig. 4A). In addition to histidine-rich proteins, we used protamine sulfate to probe iron oxide charge. Protamine sulfate is an arginine-rich polypeptide that binds to iron oxide through charge interactions²⁴. Protamine sulfate absorbed to both types of particles at the same levels (Fig. 4B). The binding of kininogen and kallikrein to the foreign surface induces activation of the kallikrein-kinin cascade²², due to the association of HMWK-kallikrein and HMWK-FXII complexes with the foreign surface and the activation of kallikrein by Factor FXII²⁵. When incubated with whole citrated human plasma, both NCL-MNW and CL-MNW induced potent activation of plasma kallikrein (Fig. 4C).

Soluble globular proteins that have a relatively great freedom of movement could penetrate the hydrogel coat by diffusion through the hydrogel pores. We immobilized plasma HMWK and its histidine-rich domain D5 on agarose beads, and tested the binding of the nanoparticles. CL-MNW and NCL-MNW showed the same binding efficiency to the immobilized cationic proteins (Fig. 5A–B) suggesting that hydrogel does not prevent interactions of nanoworms with the charged protein surface.

Discussion

It has been previously acknowledged that coating nanoparticles with neutral hydrophilic polymers decreases immune recognition and greatly delays the clearance of many nanoparticulate systems^{26, 27}. According to Torchilin and Trubetskoy²⁸, long chains of polymers such as PEG form a random cloud around the nanoparticle, thereby preventing protein absorption. PEG has been found to prevent binding of plasma proteins³. We tested the non-fouling properties of iron oxide nanoworms coated with crosslinked dextran hydrogel in an attempt to explain their long-circulating properties *in vivo*. Our data show that crosslinked dextran hydrogel efficiently prevents MNW recognition and *in vivo* clearance by reticuloendothelial system macrophages, but at the same time allows the binding of numerous plasma proteins and cationic peptides to MNW. A similar phenomenon was observed for PEGylated nanoparticles of certain compositions^{29, 30}. For example, PEG-DSPE 2000 had no effect on protein adsorption onto negatively charged liposomes composed of phosphatidic acid³⁰. It remains to be investigated whether cationic proteins are able to invade and penetrate the hydrogel coating in order to interact with the nanoparticle core, or if there exist some long-range charge interactions on the nanoparticle surface without the hydrogel layer penetration.

Our data show that total repelling of proteins is not required for prolonged circulation of iron oxide nanoparticles. More likely, the prevention of selective interactions is important for attaining these long-circulating properties. Since the molecular pathways responsible for the clearance of nanoparticles are yet to be understood, it would be difficult at this point to suggest a concrete mechanism by which hydrogel prolongs circulation. Particle size and shape play an important role in nanoparticle uptake, possibly due to the decreased ability of macrophages to engulf particles of certain dimensions and shapes^{31–34}. However, crosslinking did not significantly affect the size and aspect ratio of our particles. Since the conjugations of intact dextran to CL-MNW surface only further prolonged the clearance of MNWs, we conclude that the crosslinking effect also cannot be ascribed to the alterations of dextran structure. It is likely that there exist subtle differences in protein opsonization that could not be detected in our system. In that case, more sensitive proteomic methods to detect these differences would be required⁵. Other effects, such as the prevention of nanoparticle aggregation *in vivo*, or the inhibition of nanoparticle binding to macrophage surface³⁵, are likely to play a role in reducing uptake of the crosslinked nanoparticles. Iron oxide nanoparticles are recognized *in vitro* through scavenger receptor-based mechanisms⁴. As

scavenger-receptor signaling and its role in SPIO uptake *in vitro* and *in vivo* become better understood, new clues to nanoparticle biodistribution mechanisms are likely to emerge.

Lastly, the non-bioinert behavior of the hydrogel coatings studied here offers a variety of interesting possibilities for the design of nanoparticles and nanomedicines. There exist potential shortcomings in the non-discriminating total protein-repelling effect, such as an affinity decrease of surface-tethered ligands due to interference of the surrounding brush PEG layer³⁶, and prevention of surface reactions of nanoparticles. Uncoupling of the particles' non-fouling and long-circulating properties could help design smart "semi-stealth" nanomedicines with a broad spectrum of attractive biochemical properties.

Materials and Methods

Nanoparticle preparation and characterization

Superparamagnetic dextran iron oxide nanoworms were prepared by a precipitation method using 20 kDa dextran (Sigma-Aldrich, Saint Lewis MO) as described¹⁷. For preparation of crosslinked nanoworms (described in detail in¹⁷), 15 mg Fe was reacted in 5 mL of strong base (5N aqueous NaOH solution) containing 1 ml of epichlorohydrin (Sigma) for 24 hrs, purified by dialysis against double distilled water for 24 hrs using a dialysis cassette (10Kda MWCO, Pierce), and filtered through a 0.1 μ m PVDF membrane filter (Millipore, Billerica, MA). The exact same procedure was performed to prepare 1-chloropropane-2,3-diol-treated MNW (Sigma). All particles were stored in PBS at 4°C prior to use.

Size and ζ (zeta)-potential of nanoparticles before and after dextran modification were measured using Zetasizer Nano (Malvern, UK). For nanoparticle imaging with transmission electron microscope, 25 μ l of 0.1mg/mL Fe solution in water was placed on Formvar-/carbon-coated grids (Ted Pella, Redding, CA). After 1 minute the grid was gently blotted and air-dried. Grids were viewed using a JEOL 1200EX II (JEOL, Peabody, MA) transmission electron microscope and photographed using a Gatan digital camera (Gatan, Pleasanton, CA).

Clearance and liver uptake in mice

All the animal work was reviewed and approved by the Sanford-Burnham Medical Research Institute's Animal Research Committee. Six- to eight-week old female C57BL/6J mice were anesthetized with Avertin, and nanoparticles (1–4 mg Fe/kg body weight) were injected into the tail vein in a total volume of up to 150 μ l. Blood was collected from the periorbital vein by heparinized capillaries at different time points, and plasma was separated from cells by centrifugation using a tabletop microcentrifuge at 4000 rpm for 2 min. Fifteen microliters of plasma were collected to measure iron levels by QuantiChrom Assay (BioAssay Systems, Hayward, CA) as described⁵, and the elimination half-life was determined by Prism (GraphPad, La Jolla, CA) software by plotting the percentage of the injected dose in blood versus time. For histological analysis of nanoparticle uptake, animals were sacrificed 4 h post-injection, and liver and spleen organs were dissected, fixed in formalin, and cryosectioned; organs were subsequently stained for nanoparticle accumulation using Prussian blue stain and counterstained with Nuclear fast red.

Surface dextran probing

Dextran antibody-binding experiments were performed as described previously⁵. Briefly, 3 μ l of fluorescein-labeled anti-dextran IgG (STEMCELL Technologies Inc, Vancouver, Canada) were incubated with 100 μ g Fe for 10–15 min. The particles were pelleted by ultracentrifuge and the FITC fluorescence in the supernatant was measured using a Fuji FLA-5100 fluorescent scanner. The fluorescence associated with nanoparticles, which

corresponds to the bound antibody, was calculated as the difference in supernatant fluorescence intensity between antibody and nanoparticle supernatants. For analysis of the dextran hydroxyl groups, a modified methyl red assay was used³⁷. Nanoparticles to be analyzed were precipitated in acetone and resuspended in anhydrous DMSO at 2mg Fe/mL. A 10 milligram 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC, Thermo Fisher Scientific, Waltham, MA), 5mg methyl red (MP Biomedicals, Solon, OH), 15 mg N-hydroxysuccinimide, and 100 µl triethylamine (Sigma-Aldrich) solution was dissolved in DMSO and added to 0.5 ml of 1 mg/ml nanoparticle solution. The reaction was allowed to proceed for 5 h at 37° C. Thereafter, nanoparticles were precipitated with acetone and resuspended in water five times in order to discard the unreacted methyl red; nanoparticles were subsequently resuspended in 0.3 ml DDW. Fifty microliters of 10N HCl were added and the particles were incubated overnight. This treatment completely dissolved iron oxide, which could otherwise interfere with methyl red absorbance. The absorbance was determined at 540nm using Tecan plate reader.

Protein binding to nanoparticles

The binding was performed as described⁵. Briefly, 100 µg of iron oxide nanoparticles were incubated with 300–500 µl of fresh citrated mouse or human plasma supplemented with 10 µl mammalian protease inhibitor cocktail (Sigma), or with 100 µl of 10 mg/ml salmon sperm protamine (Sigma) in PBS, for 10 min with vortexing at room temperature. The unbound proteins were washed away 4 times using Beckman TLA-100 ultracentrifuge (70,000g for 10 min in 1ml PBS) and the pellet was boiled in 50 µl of 8M urea/1M NaCl/1M imidazole for 30 min. The mixture of particles and proteins (corresponding to 5–20 µg iron) was loaded into wells of Novex 4–20% Tris-glycine polyacrylamide gel (Invitrogen, Carlsbad, CA), and the proteins were electrophoretically separated and stained with SilverQuest kit (Invitrogen).

For immunoblotting analysis of the eluted proteins, polyclonal goat anti-mouse kallikrein (R&D Systems, Minneapolis, MN), polyclonal mouse anti-human HMWK (R&D), and polyclonal rabbit anti-mouse HMWK (provided by the laboratory of Dr. McCrae) were used.

For binding to kininogen beads, anti-human antibody was immobilized on GammaBind beads (GE Healthcare, Piscataway, NJ) according to the manufacturer's instructions. A ratio of 10 µg Ab to 100 µl beads was used. Rabbit antibody (Jackson Immuno Research, West Grove, PA) was used for the preparation of control beads. Following incubation with the antibody, the beads were washed 4 times in PBS and blocked with excess of rabbit IgG for 10 min.

For immobilizing D5-GST to glutathione-agarose, a previously described protocol was used⁵. GST immobilized on agarose was used as a control. For the nanoparticle binding assay, HMWK-beads, D5 beads, and control beads were incubated with a 0.5 mg/ml solution of nanoparticles for 10 min (50 µl beads with 50 µl of 1mg/ml Fe) and washed 4 times in 0.1% Tween-20 in PBS. A small aliquot of the beads was stained with Prussian blue³⁸ to visualize iron. The rest of the beads were mixed with 200 µl of QuantiChrom Assay overnight, and the absorbance of the supernatant was measured at 570 nm.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Ms. Emily Bass (UCSD) for assisting with manuscript preparation, and Dr. Keith McCrae (Cleveland Clinic) for providing D5-GST and the anti-mouse kininogen antibody. This work was supported by NIH NCI grants 5U54CA119335 [E.R.] and 1R21CA137721-01 [D.S.], and the UCSD Cancer Center Specialized Support Grant P30 CA23100. We would like to acknowledge the use of the UCSD Cryo-Electron Microscopy Facility, which is supported by NIH grants to Dr. Timothy S. Baker and a gift from the Agouron Institute to UCSD.

References

1. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. *Pharmacol Rev.* 2001; 53(2):283–318. [PubMed: 11356986]
2. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. *Annu Rev Immunol.* 2005; 23:901–44. [PubMed: 15771589]
3. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol Pharm.* 2008; 5(4):505–15. [PubMed: 18672949]
4. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. *Invest Radiol.* 2004; 39(1):56–63. [PubMed: 14701989]
5. Simberg D, Park JH, Karmali PP, Zhang WM, Merkulov S, McCrae K, Bhatia SN, Sailor M, Ruoslahti E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. *Biomaterials.* 2009; 30(23–24):3926–33. [PubMed: 19394687]
6. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. *NMR Biomed.* 2004; 17(7):484–99. [PubMed: 15526347]
7. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. *Magn Reson Imaging.* 1995; 13(5):661–74. [PubMed: 8569441]
8. Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. *Magn Reson Imaging.* 1995; 13(5):675–91. [PubMed: 8569442]
9. Lucas IT, Durand-Vidal S, Dubois E, Chevalet J, Turq P. Surface charge density of maghemite nanoparticles: Role of electrostatics in the proton exchange. *J Phys Chem C.* 2007; 111(50):18568–18576.
10. Simmons GW, Beard BC. Characterization of acid-base properties of the hydrated oxides on iron and titanium metal surfaces. *Langmuir.* 1987; 91(5):1143–1148.
11. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway--its role in innate immunity and evolution. *Immunol Rev.* 2004; 198:185–202. [PubMed: 15199963]
12. Chacko BK, Appukuttan PS. Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera. *Mol Immunol.* 2003; 39(15):933–9. [PubMed: 12695119]
13. Arima Y, Kawagoe M, Toda M, Iwata H. Complement activation by polymers carrying hydroxyl groups. *ACS Appl Mater Interfaces.* 2009; 1(10):2400–7. [PubMed: 20355878]
14. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. *Acad Radiol.* 2002; 9(Suppl 2):S304–6. [PubMed: 12188255]
15. Holmberg L, Lindberg B, Lindqvist B. The reaction between epichlorohydrin and polysaccharides: Part 1. Syntheses of some model substances with non-cyclic substituents. *Carbohydr Res.* 1994; 262(2):213–21. [PubMed: 7982216]
16. Denizli BK, Can HK, Rzaev ZMO, Guner A. Preparation conditions and swelling equilibria of dextran hydrogels prepared by some crosslinking agents. *Polymer.* 2004; 45(19):6431–6435.
17. Park JH, von Maltzahn G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia S, Sailor MJ. Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging. *Adv Mater.* 2008; 20:1630–1635. [PubMed: 21687830]

18. Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, Ruoslahti E, Bhatia SN, Sailor MJ. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. *Small*. 2009; 5(6):694–700. [PubMed: 19263431]
19. Sun G, Shen YI, Ho CC, Kusuma S, Gerecht S. Functional groups affect physical and biological properties of dextran-based hydrogels. *J Biomed Mater Res A*. 2009
20. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials*. 2005; 26(18):3995–4021. [PubMed: 15626447]
21. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. *Chem Rev*. 2008; 108(6):2064–110. [PubMed: 18543879]
22. Simberg D, Zhang WM, Merkulov S, McCrae K, Park JH, Sailor MJ, Ruoslahti E. Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo. *J Control Release*. 2009; 140(3):301–5. [PubMed: 19508879]
23. Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. *Immunol Cell Biol*. 2005; 83(2): 106–18. [PubMed: 15748207]
24. Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, Read EJ, Frank JA. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. *Blood*. 2004; 104(4):1217–23. [PubMed: 15100158]
25. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. *Blood*. 1997; 90(10):3819–43. [PubMed: 9354649]
26. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. *Int J Pharm*. 2006; 307(1):93–102. [PubMed: 16303268]
27. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. *Clin Pharmacokinet*. 2003; 42(5):419–36. [PubMed: 12739982]
28. Torchilin VP, Trubetskoi VS. Which polymers can make nanoparticulate drug carriers long-circulating? *Adv Drug Deliv Rev*. 1995; 16:141–155.
29. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. *Biochim Biophys Acta*. 2007; 1768(6):1367–77. [PubMed: 17400180]
30. Price ME, Cornelius RM, Brash JL. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. *Biochim Biophys Acta*. 2001; 1512(2):191–205. [PubMed: 11406096]
31. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. *Proc Natl Acad Sci U S A*. 2006; 103(13):4930–4. [PubMed: 16549762]
32. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. Shape effects of filaments versus spherical particles in flow and drug delivery. *Nat Nanotechnol*. 2007; 2(4):249–55. [PubMed: 18654271]
33. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. *Pharm Res*. 2008; 25(8):1815–21. [PubMed: 18373181]
34. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. *Pharm Res*. 2009; 26(1):244–9. [PubMed: 18548338]
35. Kamps JA, Scherphof GL. Receptor versus non-receptor mediated clearance of liposomes. *Adv Drug Deliv Rev*. 1998; 32(1–2):81–97. [PubMed: 10837637]
36. Duncanson WJ, Figa MA, Hallock K, Zalipsky S, Hamilton JA, Wong JY. Targeted binding of PLA microparticles with lipid-PEG-tethered ligands. *Biomaterials*. 2007; 28(33):4991–9. [PubMed: 17707503]
37. Komba S, Sasaki S, Machida S. A new colorimetric test for detection of hydroxyl groups in solid-phase synthesis. *Tetrahedron Letters*. 2007; 48(20):2075–2078.
38. Litovsky S, Madjid M, Zarrabi A, Casscells SW, Willerson JT, Naghavi M. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic

lesions in vivo: enhancement by tissue necrosis factor-alpha, interleukin-1beta, and interferon-gamma. *Circulation*. 2003; 107(11):1545–9. [PubMed: 12654614]

Figure 1. Epichlorohydrin treatment does not affect nanoparticle size, shape, and charge Magnetic nanoworms (MNW) were converted into crosslinked hydrogel with epichlorohydrin and analyzed as described in Materials and Methods. **A**, Reaction of epichlorohydrin (red) with glucopyranose residues caused crosslinking and alkylation of sugar hydroxyls; **B**, Transmission electron microscopy images of MNW with (CL) or without (NCL) epichlorohydrin modification. Lower images are cropped areas in the upper micrographs. Size bar, 100nm; **C**, a schematic representation of the particles before and after hydrogelation. Brown squares are Fe_3O_4 crystals; **D**, Size (upper chart) and zeta potential (lower chart) measurements of the nanoparticles before and after hydrogelation.

Figure 2. In vivo clearance of nanoparticles is decreased by hydrogelation

Mice were injected with CL-MNW or NCL-MNW (4mg/kg) and sacrificed by perfusion 4 h post-injection. **A**, Concentrations of Fe in plasma were quantified by iron assay and plotted versus time with Prism (GraphPad). CL-MNW (dotted line) and NCL-MNW (solid line) are shown. One representative experiment out of 5 is shown; **B**, Histological sections of the livers show almost complete absence of uptake of CL-MNW (right) and strong uptake of CL-MNW (left) by Kupffer cells (arrows) at 4h post-injection. One representative experiment out of five is shown; **C**, MNW half-life shows a 10-fold prolongation after crosslinking with epichlorohydrin. Chloropropanediol-treated nanoworms (CPD-MNW) did not show long-circulating properties, suggesting that alkylation of sugar hydroxyls is not sufficient and that the crosslinking function is required to attain the long-circulating effect. (CPD is a hydrated version of epichlorohydrin and, therefore, lacks the crosslinking action). P-value <0.0001. N=5 for epichlorohydrin-treated MNW, n=3 for chloropropanediol-treated MNW (CPD-MNW).

Figure 3. Hydrogelation partially destroys the dextran structure

A, FITC-labeled anti-dextran antibody was incubated with CL-MNW, with NCL-MNW, or without nanoparticles as described in Materials and Methods. The particles were pelleted down at 100,000g, and the fluorescence of the supernatant was measured. Anti-dextran IgG binding was calculated by subtracting the fluorescence of wells 3 and 4 from that of well 2; **B**, quantification of anti-dextran IgG binding. CL-MNW bound less of the anti-dextran antibody than the NCL-MNW. P-value 0.008 (n=3); **C**, the surface hydroxyl groups of MNWs were reacted with methyl red as described in Materials and Methods. Methyl red (structure shown) reacts through its carboxyl group with the hydroxyls in the presence of EDC/NHS. No conjugation to the dextran occurred without EDC. **D**, There was about 2 times more methyl red conjugated to NCL-MNW than to CL-MNW, presumably because some hydroxyl groups were consumed during the crosslinking process (n=2).

Fig. 4. Hydrogelation does not prevent absorption of iron oxide-binding proteins

CL-MNW and NCL-MNW were incubated with citrated mouse plasma or with protamine sulfate as described in Materials and Methods. **A**, The nanoparticles were washed and the proteins were eluted and analyzed by SDS-PAGE and silver staining. High molecular weight kininogen (HMWK), histidine-proline rich glycoprotein (HPRG), and plasma kallikrein further were visualized by immunoblotting with specific antibodies; note the similar amounts of proteins adhering to both types of nanoparticles; **B**, Silver staining was used to visualize protamine sulfate eluted from the nanoparticles (also shown are the gel wells loaded with equal amounts of MNW). One representative experiment out of 3 is shown; **C**, Activation of kallikrein by particles was studied by measuring plasma serine protease activity as described⁵. Micron-sized glass powder was used as a positive control of kallikrein activity. The same level of activation was observed for CL-MNW and NCL-MNW (n=3).

Fig. 5. CL-MNW and NCL-MNW bind to cationic protein-coated beads

High molecular weight kininogen or its histidine-rich domain D5 was immobilized onto agarose beads as described in Materials and Methods. **A**, HMWK bead-bound iron oxide was visualized with Prussian blue stain, making the beads appear blue. No detectable binding was observed to control antibody-coated beads (for details see Materials and Methods); note the similar levels of binding of CL and NCL MNWs; **B**, Quantification of iron oxide binding to HMWK-coated beads (red bars) and to HMWK domain D5-coated beads (black bars) with iron assay. The absorbance of control beads was subtracted. CL-MNWs and NCL-MNWs show similar efficiency of binding to the beads (n=2 for HMWK beads, n=4 for D5 beads).